[go: up one dir, main page]

WO1998034583A3 - Activite anti-angiogenique amelioree des derives constamment charges d'hormones steroidiennes - Google Patents

Activite anti-angiogenique amelioree des derives constamment charges d'hormones steroidiennes Download PDF

Info

Publication number
WO1998034583A3
WO1998034583A3 PCT/US1998/002176 US9802176W WO9834583A3 WO 1998034583 A3 WO1998034583 A3 WO 1998034583A3 US 9802176 W US9802176 W US 9802176W WO 9834583 A3 WO9834583 A3 WO 9834583A3
Authority
WO
WIPO (PCT)
Prior art keywords
permanently charged
agonist
steroid hormones
angiogenic activity
enhanced anti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/002176
Other languages
English (en)
Other versions
WO1998034583A2 (fr
Inventor
Anat Biegon
Marcus E Brewster
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmos Corp
Original Assignee
Pharmos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL12018497A external-priority patent/IL120184A/xx
Priority claimed from US08/833,074 external-priority patent/US6083990A/en
Application filed by Pharmos Corp filed Critical Pharmos Corp
Priority to JP53487698A priority Critical patent/JP2001511182A/ja
Priority to EP98903921A priority patent/EP0981337A4/fr
Priority to CA002280181A priority patent/CA2280181A1/fr
Priority to AU60562/98A priority patent/AU746007B2/en
Publication of WO1998034583A2 publication Critical patent/WO1998034583A2/fr
Publication of WO1998034583A3 publication Critical patent/WO1998034583A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention concerne l'utilisation d'agonistes ou d'antagonistes constamment chargés de stéroïdes comme compositions puissamment anti-angiogéniques, qui renferment comme principe actif un composé de formules générales I (médicament), II (anti-oestrogènes) ou III, dans lesquelles 'médicament' est un agoniste ou un antagoniste des stéroïdes, un mélange agoniste-antagoniste ou un agoniste partiel, et les substituants sont tels que définis dans la spécification.
PCT/US1998/002176 1997-02-09 1998-02-04 Activite anti-angiogenique amelioree des derives constamment charges d'hormones steroidiennes Ceased WO1998034583A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP53487698A JP2001511182A (ja) 1997-02-09 1998-02-04 ステロイドホルモンの永久に荷電された誘導体の増進された抗血管形成誘導活性
EP98903921A EP0981337A4 (fr) 1997-02-09 1998-02-04 Activite anti-angiogenique amelioree des derives constamment charges d'hormones steroidiennes
CA002280181A CA2280181A1 (fr) 1997-02-09 1998-02-04 Activite anti-angiogenique amelioree des derives constamment charges d'hormones steroidiennes
AU60562/98A AU746007B2 (en) 1997-02-09 1998-02-04 Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IL12018497A IL120184A (en) 1997-02-09 1997-02-09 Pharmaceutical compositions comprising permanently charged derivatives of steroid agonists or antagonists for preventing angiogenesis
IL120184 1997-02-09
US08/833,074 US6083990A (en) 1997-04-02 1997-04-02 Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones
US08/833,074 1997-04-02

Publications (2)

Publication Number Publication Date
WO1998034583A2 WO1998034583A2 (fr) 1998-08-13
WO1998034583A3 true WO1998034583A3 (fr) 1998-11-05

Family

ID=26323367

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/002176 Ceased WO1998034583A2 (fr) 1997-02-09 1998-02-04 Activite anti-angiogenique amelioree des derives constamment charges d'hormones steroidiennes

Country Status (5)

Country Link
EP (1) EP0981337A4 (fr)
JP (1) JP2001511182A (fr)
AU (1) AU746007B2 (fr)
CA (1) CA2280181A1 (fr)
WO (1) WO1998034583A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3046792B1 (fr) * 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP3484463B1 (fr) * 2016-08-19 2020-02-12 The United States of America, as Represented by The Secretary, Department of Health and Human Services Office of Technology Transfer Modulateurs sélectifs du récepteur des oestrogènes (serms) conférant une protection contre la dégénérescence des photorécepteurs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026720A1 (fr) * 1994-04-04 1995-10-12 Pharmos Corporation Derives constamment ioniques d'hormones steroides et leurs antagonistes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914561A (en) * 1957-08-06 1959-11-24 Wm S Merrell Co Amine derivatives of triphenylethylene
US2971001A (en) * 1959-10-21 1961-02-07 Wm S Merrell Co Quaternary salts of triphenylethanols, -ethylenes, and -ethanes
BE637389A (fr) * 1962-09-13
WO1994009764A1 (fr) * 1992-10-27 1994-05-11 Nippon Kayaku Kabushiki Kaisha Utilisation d'anti×strogenes non steroidiens pour traiter des maladies auto-immunes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026720A1 (fr) * 1994-04-04 1995-10-12 Pharmos Corporation Derives constamment ioniques d'hormones steroides et leurs antagonistes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0981337A4 *

Also Published As

Publication number Publication date
EP0981337A4 (fr) 2003-03-12
CA2280181A1 (fr) 1998-08-13
WO1998034583A2 (fr) 1998-08-13
AU6056298A (en) 1998-08-26
EP0981337A2 (fr) 2000-03-01
JP2001511182A (ja) 2001-08-07
AU746007B2 (en) 2002-04-11

Similar Documents

Publication Publication Date Title
IL140930A0 (en) Compounds and compositions for delivering active agents
IL116643A (en) Tetrahydronaphthalene derivatives as estrogen agonists/antagonists and pharmaceutical compositions comprising them
NZ331001A (en) Use of an opiate K receptor agonist as an antipruritic
MXPA01008611A (es) Compuestos y composiciones para suministrar agentes activos.
HU9801900D0 (en) Fungicidal 2-methoxybenzophenone derivatives, preparation and use thereof, fungicide compositions containing these compounds as active ingredients
AU7315301A (en) Compounds and compositions for delivering active agents
PT1093819E (pt) Compostos e composicoes para fornecimento de agentes activos
DK0850050T3 (da) Orale hurtigt-opløsende sammensætninger for dopaminagonister
YU42402A (sh) Jedinjenja karbamida koja imaju antagonističku aktivnost na muskarinski receptor
AU5699399A (en) Pyridyl-bridgehead derivatives and their analogues, pharmaceutical compositions and their use as inhibitors of nicotinic cholinergic receptors
SK157899A3 (en) Substituted pyrazoles as p38 kinase inhibitors, process for their preparation and pharmaceutical compositions
EP0663401A4 (fr) Derive de morphinane et application medicale.
HUP9900582A3 (en) Halogen pyrimidine derivatives, intermediates, preparation and use thereof, pesticide compositions containing these compounds as active ingredients
HUP0004150A3 (en) Indazole derivatives as tyrosine kinase receptor antagonists and pharmaceutical compositions containing them
ATE359761T1 (de) Unpolarer spray zur bukkalen anwendung die alkaloidderivate oder analgetika enthält
HUP0200992A3 (en) Indoline derivatives as progesterone antagonists and pharmaceutical compositions containing them and their use
MXPA03000548A (es) Combinacion novedosa de agonista (5-ht2) y antagonistas (5-ht6) de serotonina como formulacion farmaceutica.
EP1211951A4 (fr) Procede pour fabriquer une gomme a macher pharmaceutique
WO2001014406A8 (fr) Agents anti-androgènes
AU3492100A (en) Oxadiazole compounds and compositions for delivering active agents
HUP9901596A3 (en) Pyrazole derivatives, intermediates, preparation and use thereof, herbicide compositions containing these compounds as active ingredients
BG105136A (en) 4,5,6 and 7-indole and indoline derivatives, their preparation and use
WO2002015959A3 (fr) Composes et compositions permettant de distribuer des agents actifs
ES2189252T3 (es) Composiciones analgesicas que comprenden un antagonista de la colecistoquinina y un opioide.
WO2000073269A3 (fr) Ligands du recepteur nicotinique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE GH GW HU ID IL IS JP KG KP KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE GH GW HU ID IL IS JP KG KP KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2280181

Country of ref document: CA

Ref country code: CA

Ref document number: 2280181

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 1998 534876

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 60562/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998903921

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998903921

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 60562/98

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1998903921

Country of ref document: EP